NewcelX Announces Collaborative Research Agreement with Eledon Pharmaceuticals
NewcelX (NCEL) announced a collaborative research agreement with Eledon Pharmaceuticals (ELDN). The collaboration is designed to advance combination strategies integrating NewcelX's lead program, NCEL-101, with Eledon's investigational anti-CD40L monoclonal antibody, tegoprubart, with the goal of supporting durable, immune-protected islet replacement and advancing a potential functional cure for Type 1 Diabetes.
